Leila Zakka

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer.

Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 06, 2026

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 06, 2026

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.

Journal: Nature cancer

Published: July 18, 2025

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

Journal: Cell

Published: January 23, 2025

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.

Journal: The Lancet. Digital health

Published: January 10, 2024

Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.

Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.

Journal: PloS one

Published: June 05, 2023

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.

Journal: Research square

Published: February 17, 2023

Author Correction: The white matter is a pro-differentiative niche for glioblastoma.

Author Correction: The white matter is a pro-differentiative niche for glioblastoma.

Journal: Nature communications

Published: April 15, 2022

Accumulation of copy number alterations and clinical progression across advanced prostate cancer.

Accumulation of copy number alterations and clinical progression across advanced prostate cancer.

Journal: Genome medicine

Published: January 13, 2022

The white matter is a pro-differentiative niche for glioblastoma.

The white matter is a pro-differentiative niche for glioblastoma.

Journal: Nature communications

Published: January 12, 2021

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Journal: Nature medicine

Published: June 07, 2017

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Journal: Nature medicine

Published: April 08, 2017

Showing 1-12 of 14

Last Updated: 09/26/2026